Palisade Bio, Inc. (PALI)

USD 1.75

(-7.89%)

Market Cap (In USD)

2.92 Million

Revenue (In USD)

250 Thousand

Net Income (In USD)

-12.3 Million

Avg. Volume

63.44 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.38-22.35
PE
-
EPS
-
Beta Value
1.331
ISIN
US6963892046
CUSIP
696389105
CIK
1357459
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. J. D. Finley
Employee Count
-
Website
https://www.palisadebio.com
Ipo Date
2007-03-30
Details
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.